Revenue Summary of Enzon Pharmaceuticals, Inc.

Enzon Pharmaceuticals, Inc.'s latest annual revenue in 2023 was - USD , down -100.0% from previous year.
Enzon Pharmaceuticals, Inc.'s latest quarterly revenue in 2024 Q1 was - USD , down 0.0% from previous quarter.
Enzon Pharmaceuticals, Inc. reported a annual revenue of 26 Thousand USD in annual revenue 2022, down -96.29% from previous year.
Enzon Pharmaceuticals, Inc. reported a annual revenue of 701 Thousand USD in annual revenue 2021, up 1248.08% from previous year.
Enzon Pharmaceuticals, Inc. reported a quarterly revenue of - USD for 2024 Q1, down 0.0% from previous quarter.
Enzon Pharmaceuticals, Inc. reported a quarterly revenue of - USD for 2024 Q3, down -100.0% from previous quarter.

Annual Revenue Chart of Enzon Pharmaceuticals, Inc. (2023 - 1989)

Historical Annual Revenue of Enzon Pharmaceuticals, Inc. (2023 - 1989)

Year	Revenue	Revenue Growth
2023	- USD	-100.0%
2022	26 Thousand USD	-96.29%
2021	701 Thousand USD	1248.08%
2020	52 Thousand USD	-74.88%
2019	207 Thousand USD	-97.01%
2018	6.91 Million USD	-17.44%
2017	8.37 Million USD	0.02%
2016	8.37 Million USD	-52.01%
2015	17.45 Million USD	-44.0%
2014	31.17 Million USD	-9.63%
2013	34.49 Million USD	-19.03%
2012	42.6 Million USD	-11.38%
2011	48.07 Million USD	-50.88%
2010	97.86 Million USD	-46.99%
2009	184.62 Million USD	-6.25%
2008	196.93 Million USD	6.11%
2007	185.6 Million USD	-0.03%
2006	185.65 Million USD	0.0%
2005	- USD	-100.0%
2004	169.57 Million USD	15.82%
2003	146.4 Million USD	93.14%
2002	75.8 Million USD	139.98%
2001	31.58 Million USD	85.62%
2000	17.01 Million USD	28.92%
1999	13.2 Million USD	-9.59%
1998	14.6 Million USD	14.96%
1997	12.7 Million USD	0.0%
1996	12.7 Million USD	-19.62%
1995	15.8 Million USD	6.76%
1994	14.8 Million USD	76.19%
1993	8.4 Million USD	47.37%
1992	5.7 Million USD	137.5%
1991	2.4 Million USD	-4.0%
1990	2.5 Million USD	-7.41%
1989	2.7 Million USD	800.0%

Year	Revenue	Revenue Growth
2024 Q2	26 Thousand USD	0.0%
2024 Q1	- USD	0.0%
2024 Q3	- USD	-100.0%
2023 Q2	- USD	0.0%
2023 Q1	- USD	-100.0%
2023 Q4	- USD	0.0%
2023 Q3	- USD	0.0%
2023 FY	- USD	-100.0%
2022 Q2	- USD	0.0%
2022 Q1	- USD	-100.0%
2022 FY	26 Thousand USD	-96.29%
2022 Q4	26 Thousand USD	0.0%
2022 Q3	- USD	0.0%
2021 Q2	291 Thousand USD	-23.62%
2021 Q1	381 Thousand USD	1020.59%
2021 FY	701 Thousand USD	1248.08%
2021 Q3	- USD	-100.0%
2021 Q4	29 Thousand USD	0.0%
2020 Q3	8000.00 USD	0.0%
2020 Q4	34 Thousand USD	325.0%
2020 FY	52 Thousand USD	-74.88%
2020 Q1	2000.00 USD	-95.92%
2020 Q2	8000.00 USD	300.0%
2019 Q4	49 Thousand USD	2350.0%
2019 Q3	2000.00 USD	-99.03%
2019 FY	207 Thousand USD	-97.01%
2019 Q2	207 Thousand USD	505.88%
2019 Q1	-51 Thousand USD	-100.72%
2018 FY	6.91 Million USD	-17.44%
2018 Q1	15 Thousand USD	15.38%
2018 Q3	-280 Thousand USD	-559.02%
2018 Q2	61 Thousand USD	306.67%
2018 Q4	7.12 Million USD	2643.93%
2017 Q2	6.77 Million USD	370.49%
2017 Q3	151 Thousand USD	-97.77%
2017 Q4	13 Thousand USD	-91.39%
2017 FY	8.37 Million USD	0.02%
2017 Q1	1.44 Million USD	68.82%
2016 Q4	853 Thousand USD	-57.05%
2016 FY	8.37 Million USD	-52.01%
2016 Q2	2.27 Million USD	-30.43%
2016 Q3	1.98 Million USD	-12.59%
2016 Q1	3.26 Million USD	3.22%
2015 Q4	3.16 Million USD	-17.58%
2015 Q2	5.19 Million USD	-1.31%
2015 FY	17.45 Million USD	-44.0%
2015 Q3	3.83 Million USD	-26.06%
2015 Q1	5.26 Million USD	-16.07%
2014 Q4	6.26 Million USD	-23.22%
2014 Q1	8.97 Million USD	20.86%
2014 Q2	7.76 Million USD	-13.47%
2014 Q3	8.16 Million USD	5.12%
2014 FY	31.17 Million USD	-9.63%
2013 Q1	10.18 Million USD	-4.36%
2013 Q4	7.42 Million USD	-15.88%
2013 Q3	8.82 Million USD	9.58%
2013 Q2	8.05 Million USD	-20.89%
2013 FY	34.49 Million USD	-19.03%
2012 FY	42.6 Million USD	-11.38%
2012 Q4	10.64 Million USD	-4.26%
2012 Q3	11.12 Million USD	8.7%
2012 Q2	10.23 Million USD	-3.49%
2012 Q1	10.6 Million USD	5.89%
2011 Q4	10.01 Million USD	-4.11%
2011 Q3	10.44 Million USD	8.76%
2011 Q2	9.59 Million USD	-46.74%
2011 Q1	18.02 Million USD	41.26%
2011 FY	48.07 Million USD	-50.88%
2010 Q1	58.16 Million USD	31.62%
2010 FY	97.86 Million USD	-46.99%
2010 Q2	13.71 Million USD	-76.42%
2010 Q3	13.23 Million USD	-3.55%
2010 Q4	12.75 Million USD	-3.57%
2009 Q4	44.18 Million USD	-0.92%
2009 Q3	44.6 Million USD	-5.49%
2009 Q2	47.19 Million USD	-2.97%
2009 Q1	48.63 Million USD	0.47%
2009 FY	184.62 Million USD	-6.25%
2008 Q4	48.41 Million USD	-0.78%
2008 Q3	48.79 Million USD	-4.27%
2008 Q1	48.77 Million USD	1.48%
2008 Q2	50.96 Million USD	4.49%
2008 FY	196.93 Million USD	6.11%
2007 Q4	48.06 Million USD	2.6%
2007 Q2	49.21 Million USD	18.62%
2007 FY	185.6 Million USD	-0.03%
2007 Q3	46.84 Million USD	-4.82%
2007 Q1	41.48 Million USD	-12.59%
2006 FY	185.65 Million USD	0.0%
2006 Q4	47.46 Million USD	3.51%
2006 Q3	45.85 Million USD	-3.67%
2006 Q2	47.6 Million USD	6.43%
2006 Q1	44.72 Million USD	0.0%
2005 FY	- USD	-100.0%
2005 Q4	- USD	-100.0%
2005 Q3	44.04 Million USD	-0.21%
2005 Q2	44.14 Million USD	13.94%
2005 Q1	38.73 Million USD	-9.73%
2004 Q1	44.37 Million USD	6.43%
2004 FY	169.57 Million USD	15.82%
2004 Q3	40.45 Million USD	-5.59%
2004 Q4	42.91 Million USD	6.09%
2004 Q2	42.85 Million USD	-3.45%
2003 Q3	40.64 Million USD	-12.93%
2003 Q2	46.67 Million USD	8.14%
2003 Q1	43.16 Million USD	37.04%
2003 Q4	41.69 Million USD	2.59%
2003 FY	146.4 Million USD	93.14%
2002 Q1	19.84 Million USD	6.68%
2002 Q2	25.21 Million USD	27.07%
2002 Q4	31.49 Million USD	25.65%
2002 Q3	25.06 Million USD	-0.59%
2002 FY	75.8 Million USD	139.98%
2001 Q4	18.6 Million USD	53.18%
2001 FY	31.58 Million USD	85.62%
2001 Q1	9.93 Million USD	65.0%
2001 Q2	10.46 Million USD	5.35%
2001 Q3	12.14 Million USD	16.06%
2000 Q4	6.01 Million USD	16.34%
2000 Q1	5.72 Million USD	50.61%
2000 Q2	4.61 Million USD	-19.35%
2000 Q3	5.17 Million USD	12.09%
2000 FY	17.01 Million USD	28.92%
1999 Q2	3.3 Million USD	6.45%
1999 FY	13.2 Million USD	-9.59%
1999 Q3	2.9 Million USD	-12.12%
1999 Q4	3.8 Million USD	31.03%
1999 Q1	3.1 Million USD	-18.42%
1998 Q3	3 Million USD	-3.23%
1998 FY	14.6 Million USD	14.96%
1998 Q2	3.1 Million USD	19.23%
1998 Q4	3.8 Million USD	26.67%
1998 Q1	2.6 Million USD	-38.1%
1997 Q1	2.4 Million USD	-33.33%
1997 Q2	2.9 Million USD	20.83%
1997 FY	12.7 Million USD	0.0%
1997 Q4	4.2 Million USD	-10.64%
1997 Q3	4.7 Million USD	62.07%
1996 Q2	3.7 Million USD	37.04%
1996 Q1	2.7 Million USD	-18.18%
1996 Q4	3.6 Million USD	-5.26%
1996 FY	12.7 Million USD	-19.62%
1996 Q3	3.8 Million USD	2.7%
1995 FY	15.8 Million USD	6.76%
1995 Q3	2.9 Million USD	-40.82%
1995 Q2	4.9 Million USD	2.08%
1995 Q1	4.8 Million USD	118.18%
1995 Q4	3.3 Million USD	13.79%
1994 Q1	7.7 Million USD	285.0%
1994 Q2	3 Million USD	-61.04%
1994 Q3	3.9 Million USD	30.0%
1994 Q4	2.2 Million USD	-43.59%
1994 FY	14.8 Million USD	76.19%
1993 Q4	2 Million USD	-4.76%
1993 Q1	2 Million USD	-9.09%
1993 Q2	2.4 Million USD	20.0%
1993 FY	8.4 Million USD	47.37%
1993 Q3	2.1 Million USD	-12.5%
1992 Q4	2.2 Million USD	22.22%
1992 Q1	1.3 Million USD	0.0%
1992 FY	5.7 Million USD	137.5%
1992 Q2	2 Million USD	53.85%
1992 Q3	1.8 Million USD	-10.0%
1991 Q3	1.2 Million USD	33.33%
1991 FY	2.4 Million USD	-4.0%
1991 Q1	700 Thousand USD	-12.5%
1991 Q2	900 Thousand USD	28.57%
1991 Q4	1.3 Million USD	8.33%
1990 Q2	600 Thousand USD	0.0%
1990 Q3	100 Thousand USD	-83.33%
1990 Q4	800 Thousand USD	700.0%
1990 Q1	600 Thousand USD	0.0%
1990 FY	2.5 Million USD	-7.41%
1989 Q3	600 Thousand USD	200.0%
1989 Q4	600 Thousand USD	0.0%
1989 Q2	200 Thousand USD	-60.0%
1989 Q1	500 Thousand USD	-37.5%
1989 FY	2.7 Million USD	800.0%

Peer Revenue Comparison of Enzon Pharmaceuticals, Inc.

Name	Revenue	Revenue Difference
Burzynski Research Institute, Inc.	- USD	NaN%
Arch Therapeutics, Inc.	75.72 Thousand USD	100.0%
Evofem Biosciences, Inc.	18.21 Million USD	100.0%
Nascent Biotech, Inc.	- USD	NaN%
Rebus Holdings, Inc.	- USD	NaN%
Santhera Pharmaceuticals Holding AG	122.95 Million USD	100.0%
Qrons Inc.	- USD	NaN%
Adynxx, Inc.	- USD	NaN%
Neon Bloom, Inc.	- USD	NaN%
Northwest Biotherapeutics, Inc.	1.93 Million USD	100.0%
ProtoKinetix, Incorporated	- USD	NaN%
Skye Bioscience, Inc.	- USD	NaN%
Eiger BioPharmaceuticals, Inc.	15.77 Million USD	100.0%
Nanobac Pharmaceuticals, Incorporated	17.62 Thousand USD	100.0%
Institute of Biomedical Research Corp.	- USD	NaN%
SQZ Biotechnologies Company	21.47 Million USD	100.0%
Intellipharmaceutics International Inc.	65.72 Thousand USD	100.0%
Propanc Biopharma, Inc.	- USD	NaN%
Mesoblast Limited	5.9 Million USD	100.0%
Marizyme, Inc.	645.81 Thousand USD	100.0%
Genus plc	668.8 Million USD	100.0%
VioQuest Pharmaceuticals, Inc.	- USD	NaN%
Pharming Group N.V.	245.31 Million USD	100.0%
Therapeutic Solutions International, Inc.	98.99 Thousand USD	100.0%
CNBX Pharmaceuticals Inc.	410.16 Thousand USD	100.0%
Nymox Pharmaceutical Corporation	- USD	NaN%
ContraFect Corporation	- USD	NaN%
PsyBio Therapeutics Corp.	- USD	NaN%
Sienna Biopharmaceuticals, Inc.	- USD	NaN%
RegeneRx Biopharmaceuticals, Inc.	76.76 Thousand USD	100.0%
IMV Inc.	- USD	NaN%
AXIM Biotechnologies, Inc.	39.51 Thousand USD	100.0%
MultiCell Technologies, Inc.	49.32 USD	100.0%
ONE Bio Corp.	52.29 Million USD	100.0%
Accustem Sciences Inc.	- USD	NaN%
RVL Pharmaceuticals plc	49.72 Million USD	100.0%
Arno Therapeutics, Inc.	- USD	NaN%
EV Biologics, Inc.	48.9 Thousand USD	100.0%
Q BioMed Inc.	284.35 Thousand USD	100.0%
Emmaus Life Sciences, Inc.	29.59 Million USD	100.0%
Mosaic ImmunoEngineering Inc.	- USD	NaN%
Biomind Labs Inc.	- USD	NaN%
American Oriental Bioengineering, Inc.	145.09 Million USD	100.0%
Provectus Biopharmaceuticals, Inc.	557.71 Thousand USD	100.0%
TetraLogic Pharmaceuticals Corporation	- USD	NaN%
Oncotelic Therapeutics, Inc.	70 Thousand USD	100.0%
GlobeStar Therapeutics Corporation	- USD	NaN%
THC Farmaceuticals, Inc.	- USD	NaN%
Acro Biomedical Co., Ltd.	658.5 Thousand USD	100.0%
Curative Biotechnology, Inc.	- USD	NaN%
GB Sciences, Inc.	- USD	NaN%
Alpha Cognition Inc.	- USD	NaN%
HST Global, Inc.	- USD	NaN%
CSL Limited	14.69 Billion USD	100.0%
Wesana Health Holdings Inc.	- USD	NaN%
Halberd Corporation	999.00 USD	100.0%
Enzolytics Inc.	52.79 Thousand USD	100.0%
Agentix Corp.	- USD	NaN%
Resverlogix Corp.	- USD	NaN%
Nuo Therapeutics, Inc.	608.52 Thousand USD	100.0%
MetaStat, Inc.	- USD	NaN%
argenx SE	1.22 Billion USD	100.0%
Endonovo Therapeutics, Inc.	140.24 Thousand USD	100.0%
RespireRx Pharmaceuticals Inc.	- USD	NaN%
GeneThera, Inc.	- USD	NaN%
Inhibitor Therapeutics, Inc.	- USD	NaN%
AVAX Technologies, Inc.	617.38 Thousand USD	100.0%
Zenith Capital Corp.	- USD	NaN%
Genscript Biotech Corporation	839.52 Million USD	100.0%
Ember Therapeutics, Inc.	- USD	NaN%
Anthera Pharmaceuticals, Inc.	- USD	NaN%
Sigyn Therapeutics, Inc.	- USD	NaN%
WPD Pharmaceuticals Inc.	- USD	NaN%
Cotinga Pharmaceuticals Inc.	- USD	NaN%
Kadimastem Ltd	- USD	NaN%
Helix BioMedix, Inc.	997.72 Thousand USD	100.0%
VitaSpring Biomedical Co. Ltd.	- USD	NaN%
Capstone Therapeutics Corp.	48.35 Million USD	100.0%
BioStem Technologies, Inc.	16.68 Million USD	100.0%
Oncology Pharma Inc.	- USD	NaN%
Reve Technologies, Inc.	- USD	NaN%
LadRx Corporation	- USD	NaN%
Cell Source, Inc.	- USD	NaN%
Regen BioPharma, Inc.	236.56 Thousand USD	100.0%
Regen BioPharma, Inc.	236.56 Thousand USD	100.0%
NovAccess Global Inc.	- USD	NaN%
Affymax, Inc.	1.36 Million USD	100.0%
Itoco Inc.	- USD	NaN%
Rasna Therapeutics, Inc.	- USD	NaN%
Pathfinder Cell Therapy, Inc.	- USD	NaN%
Mobile Lads Corp.	- USD	NaN%
CytoDyn Inc.	- USD	NaN%
Claritas Pharmaceuticals, Inc.	- USD	NaN%
NDT Pharmaceuticals Inc.	- USD	NaN%
NanoSphere Health Sciences Inc.	- USD	NaN%
Alseres Pharmaceuticals, Inc.	473.73 Thousand USD	100.0%
SYBLEU INC	11.69 Thousand USD	100.0%
Advanced Proteome Therapeutics Corporation	- USD	NaN%
ImmunoCellular Therapeutics, Ltd.	- USD	NaN%
International Stem Cell Corporation	7.78 Million USD	100.0%
Bioxytran, Inc.	- USD	NaN%
GlobeImmune, Inc.	- USD	NaN%
Predictive Technology Group, Inc.	- USD	NaN%
ProText Mobility, Inc.	- USD	NaN%
Cardax, Inc.	- USD	NaN%
VG Life Sciences Inc.	- USD	NaN%
Kaleido Biosciences, Inc.	- USD	NaN%
Advaxis, Inc.	13 Thousand USD	100.0%
Adhera Therapeutics, Inc.	- USD	NaN%
RenovaCare, Inc.	- USD	NaN%
Regnum Corp.	- USD	NaN%
Innovation Pharmaceuticals Inc.	- USD	NaN%
Neutra Corp.	39.53 Thousand USD	100.0%
Windtree Therapeutics, Inc.	- USD	NaN%
PureTech Health plc	3.33 Million USD	100.0%
Coeptis Therapeutics, Inc.	- USD	NaN%
IXICO plc	6.66 Million USD	100.0%
IntelGenx Technologies Corp.	1.03 Million USD	100.0%
Gelesis Holdings, Inc.	25.76 Million USD	100.0%
CSL Limited	14.8 Billion USD	100.0%
Cellectis S.A.	755 Thousand USD	100.0%

Global Stocks Search

Enzon Pharmaceuticals, Inc. (ENZN)

Revenue Summary of Enzon Pharmaceuticals, Inc.

Annual Revenue Chart of Enzon Pharmaceuticals, Inc. (2023 - 1989)

Historical Annual Revenue of Enzon Pharmaceuticals, Inc. (2023 - 1989)

Peer Revenue Comparison of Enzon Pharmaceuticals, Inc.